GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AdaptHealth Corp (NAS:AHCO) » Definitions » Debt-to-EBITDA

AdaptHealth (AdaptHealth) Debt-to-EBITDA : -3.93 (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is AdaptHealth Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

AdaptHealth's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $92 Mil. AdaptHealth's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2,203 Mil. AdaptHealth's annualized EBITDA for the quarter that ended in Dec. 2023 was $-583 Mil. AdaptHealth's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -3.93.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for AdaptHealth's Debt-to-EBITDA or its related term are showing as below:

AHCO' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -10.89   Med: 4.17   Max: 5.21
Current: -10.89

During the past 7 years, the highest Debt-to-EBITDA Ratio of AdaptHealth was 5.21. The lowest was -10.89. And the median was 4.17.

AHCO's Debt-to-EBITDA is ranked worse than
100% of 429 companies
in the Medical Devices & Instruments industry
Industry Median: 1.21 vs AHCO: -10.89

AdaptHealth Debt-to-EBITDA Historical Data

The historical data trend for AdaptHealth's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AdaptHealth Debt-to-EBITDA Chart

AdaptHealth Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial 5.21 -9.82 4.36 4.17 -10.89

AdaptHealth Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.28 4.16 3.80 -1.61 -3.93

Competitive Comparison of AdaptHealth's Debt-to-EBITDA

For the Medical Devices subindustry, AdaptHealth's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AdaptHealth's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AdaptHealth's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where AdaptHealth's Debt-to-EBITDA falls into.



AdaptHealth Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

AdaptHealth's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(91.76 + 2202.889) / -210.702
=-10.89

AdaptHealth's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(91.76 + 2202.889) / -583.344
=-3.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


AdaptHealth  (NAS:AHCO) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


AdaptHealth Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of AdaptHealth's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


AdaptHealth (AdaptHealth) Business Description

Traded in Other Exchanges
N/A
Address
220 West Germantown Pike, Suite 250, Plymouth Meeting, PA, USA, 19462
AdaptHealth Corp is engaged in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. It focuses on providing; sleep therapy equipment, supplies, and related services (including CPAP and bi-PAP services) to individuals suffering from obstructive sleep apnea (OSA), medical devices and supplies to patients for the treatment of diabetes (including continuous glucose monitors (CGM and insulin pumps), home medical equipment to patients discharged from acute care and other facilities, oxygen and related chronic therapy services in the home, and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy and nutritional supply needs.
Executives
Williams David Solomon Iii director 6272 CONDON AVE, LOS ANGELES CA 90056
Skyknight Aero Holdings, Llc director C/O SKYKNIGHT CAPITAL, L.P., ONE LETTERMAN DR., BLDG. C, SUITE 3-950, SAN FRANCISCO CA 94129
Albert A. Prast officer: Chief Technology Officer 3325 BARTLETT BLVD., ORLANDO FL 32811
Jason A Clemens officer: Chief Financial Officer 220 WEST GERMANTOWN PIKE, SUITE 250, C/O ADAPTHEALTH LLC, PLYMOUTH MEETING PA 19462
Christine E. Archbold officer: Chief Accounting Officer FRIARS HOUSE, 160 BLACKFRIARS ROAD, LONDON X0 SEL 8EZ
Everest Hill Group Inc. 10 percent owner TROPIC ISLE BUILDING, P O BOX 3331, ROAD TOWN TORTOLA D8 VG 1110
Daniel Bunting officer: COO - Branch Operations 12200 N.W. AMBASSADOR DRIVE, SUITE 326, KANSAS CITY MO 64163
Shaw Rietkerk officer: Chief Revenue Officer C/O ADAPTHEALTH LLC, 220 WEST GERMANTOWN PIKE, SUITE 250, PLYMOUTH MEETING PA 19462
Christopher J Joyce officer: General Counsel C/O ALLIANCE ENTERTAINMENT CORP, 110 EAST 59TH STREET 18TH FLOOR, NEW YORK NY 10022
Skyknight Aero Holdings Ii, Llc director C/O SKYKNIGHT CAPITAL, L.P., ONE LETTERMAN DR., BLDG. C, SUITE 3-950, SAN FRANCISCO CA 94129
Skyknight Capital, L.p. director C/O SKYKNIGHT CAPITAL, ONE LETTERMAN DR., BLDG. C, SUITE 3-950, SAN FRANCISCO CA 94129
Skyknight Capital Fund Ii, L.p. director ONE LETTERMAN DRIVE, BUILDING C, SUITE 3-950, SAN FRANCISCO CA 94129
Stephen P Griggs director, officer: Co-Chief Executive Officer 1360 PLACE VENDOME, WINTER PARK FL 32789
Gregory Belinfanti director 7500 RIALTO BLVD, BLDG TWO, STE 100, AUSTIN TX 78735
Frank Mullen officer: Chief Accounting Officer 4553 GLENCOE AVENUE, SUITE 300, LOS ANGELES CA 90292

AdaptHealth (AdaptHealth) Headlines

From GuruFocus